Masks Strongly Recommended but Not Required in Maryland, Starting Immediately
Due to the downward trend in respiratory viruses in Maryland, masking is no longer required but remains strongly recommended in Johns Hopkins Medicine clinical locations in Maryland. Read more.
NIBIB R01, “Dose Reduction in Pediatric Molecular Imaging,” PI: G. Sgouros, 05/2017-02/2023, Total Award Amount: $2,677,814
NCI R01, “Dose-Response in Radionuclide Therapy,” PI: G. Sgouros, 07/2018-06/2023, Total Award Amount: $3,335,047
NCI R01, “Combination Radiopharmaceutical Therapy and External Beam Radiotherapy,” PI: G. Sgouros, 09/2020-06/2025, Total Award Amount: $2,815,939
NIH R01, “Hyperspectral Single Photon Imaging of Targeted Alpha-Emitters,” PI: Y. Du/E. Frey/LJ. Meng, 07/2021-03/2025, Total Award Amount: $2,319,931
NIH U01, “High Energy and Spatial Resolution Multi-Isotope SPECT Imaging of Targeted Alpha-Emitters and their Daughters,” PI: G. Sgouros/E. Frey/Y. Du/LJ. Meng, 09/2021-05/2026, Total Award Amount: $3,827,636
NCI (via Rapid LLC), “Treatment optimization by combined alpha-emitter (alphaRPT)//radiotherapy (XRT) dosimetry for prostate cancer patients,” PI: E. Frey, 09/2019- 09/2022, Total Award Amount: $495,369
CDMRP, “Targeting GPNMB in Renal Tumors in Tuberous Sclerosis Complex and Translocation Renal Cell Carcinoma,” PD: K. Asrani,07/2022-06/2025, Total Award Amount (including Indirect Costs): $982,500
NIH R01, “Management of Unresectable Solid Tumors in the Liver by Engineered alpha-particle Radiotherapy,” PD: S. Sofou, 04/2023-03/2027, Total Award Amount (including Indirect Costs): $2,750,497
CDMRP/DOD, “Alpha-particle Radionuclide Therapy for Effective Control of Advanced, Soft-Tissue Metastatic Prostate Cancer: Focus on Low Toxicities and Quality of Life,”PD: S. Sofou, 09/2022-08/2024, Total Award Amount (including Indirect Costs): $1,227,231
CDMRP/DOD, “Alpha-particle radionuclide therapy for effective control of established, soft-tissue breast cancer metastases,”PD: S. Sofou, 09/2022-08/2024,Total Award Amount (including Indirect Costs): $1,637,499
CDMRP/DOD, “Alpha-particle radiotherapy for metastatic breast cancer to the brain,”PD: S. Sofou, 09/2022-08/2024, Total Award Amount (including Indirect Costs): $736,785
NIBIB R01, “Dose Reduction in Pediatric Molecular Imaging,” PI: G. Sgouros, 09/2022-08/2027, Total Award Amount: $3,651,845
NIH R01, “Alpha-Emitter Therapy of Osteosarcoma,” PI: G. Sgouros/D. Kraitchman, 04/02023-03/2028, Total Award Amount: $3,974,821
NIH R21, “Exosome-mediated therapy for liver cancer,” PD/PI: Y. Fu, 04/02023-03/2028, Total Award Amount: $450,312
